PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: VIGILAIR Systems, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Memorial Sloan-Kettering Cancer Center Implements New Lab Disinfection System - Genetic researchers have a greener way to keep their labs free from organic contamination. A new technology utilizing Ultraviolet light replaces manual cleaning. The technology is safe, effective and environmentally friendly - VIGILAIRSystems.com
Memorial Sloan-Kettering Cancer Center Implements New Lab Disinfection System

 

NewswireToday - /newswire/ - North Tonawanda, NY, United States, 2009/02/03 - Genetic researchers have a greener way to keep their labs free from organic contamination. A new technology utilizing Ultraviolet light replaces manual cleaning. The technology is safe, effective and environmentally friendly - VIGILAIRSystems.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The gene therapy research community is turning to a novel technology to keep their lab free from contamination. Gene therapy research labs require extremely high standards for cleanliness. Traditionally researchers at Memorial Sloan Kettering Cancer Center (MSKCC) relied on manual surface cleaning using caustic chemicals to meet those standards.

Managers at the Gene Transfer and Somatic Cell Engineering Facility were looking for an alternative because the existing cleaning procedure is labor intensive, costly and yields mixed results.

A VIGILAIR® Room Surface Sterilization System (RSS) was installed in the lab to determine its efficacy in reducing microorganisms that could contaminate the work area. Separate tests by MSKCC and VIGILAIR® showed the RSS system provided a 5 log or greater reduction on target pathogens.

RSS uses Ultraviolet energy (UV-C) to deactivate microorganisms that contaminate surfaces. UV-C emitters are strategically placed to bathe the entire lab with germicidal UV-C energy. RSS features sophisticated controls that turn off the emitters when a predetermined UV dose is achieved. The system also prevents lab workers from being accidentally exposed to UV.

“The testing results are very encouraging, “ says VIGILAIR Systems, Inc. President Peter Bjorkman. “The results clearly demonstrate that our UV technology is a safe and cost effective alternative to manual cleaning.”

About VIGILAIR Systems, Inc.

VIGILAIR Systems (vigilairsystems.com) is the industry leader in the use of evidence based design for UV surface and air disinfection. Based in New York State, VIGILAIR® serves clients worldwide. VIGILAIR® major market segments are Healthcare, Nutraceutical Manufacturing and Bio-Defense.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: VIGILAIR Systems, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Memorial Sloan-Kettering Cancer Center Implements New Lab Disinfection System

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Joel Dombrowski - VIGILAIRSystems.com 
716-692-8843 Joel.Dombrowski[.]VIGILAIRsystems.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any VIGILAIR Systems, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From VIGILAIR Systems, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)